Abeona Therapeutics Inc. (ABEO) Reaches $15.70 After 7.00% Down Move; Needham Investment Management Cut By $367,200 Its Becton Dickinson & Co (BDX) Position

June 14, 2018 - By Charlene Higgins

Becton, Dickinson and Company (NYSE:BDX) Logo

The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) is a huge mover today! The stock decreased 2.48% or $0.4 during the last trading session, reaching $15.7. About 501,319 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 191.23% since June 14, 2017 and is uptrending. It has outperformed by 178.66% the S&P500. Some Historical ABEO News: ; 15/05/2018 – Castle Hook Partners LP Exits Position in Abeona Therapeutics; 18/05/2018 – ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS lllA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING; 16/03/2018 – ABEONA THERAPEUTICS WITHDRAWS FORM S-1; 16/03/2018 – ABEONA THERAPEUTICS SAYS WITHDRAWN FORM S-1 WAS FILED FEB. 21; 06/04/2018 – Check out today’s peer review: Abeona appoints new chief as Timothy Miller moves to CSO; Maxine Gowen passes Trevena baton to Carrie Bourdow; Scott Smith out in Celgene revamp; 02/04/2018 – Abeona Therapeutics: Timothy Miller Will Remain President and Assume Position of Chief Scientific Officer; 23/04/2018 – ABEONA REPORTS FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE; 18/05/2018 – ABEONA THERAPEUTICS INC – ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED; 14/05/2018 – Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors; 15/03/2018 – ABEO GETS FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202The move comes after 9 months negative chart setup for the $742.69M company. It was reported on Jun, 14 by Barchart.com. We have $14.60 PT which if reached, will make NASDAQ:ABEO worth $51.99 million less.

Needham Investment Management Llc decreased Becton Dickinson & Co (BDX) stake by 5.96% reported in 2018Q1 SEC filing. Needham Investment Management Llc sold 1,700 shares as Becton Dickinson & Co (BDX)’s stock declined 0.58%. The Needham Investment Management Llc holds 26,800 shares with $5.81M value, down from 28,500 last quarter. Becton Dickinson & Co now has $62.04 billion valuation. The stock decreased 0.04% or $0.09 during the last trading session, reaching $232.17. About 395,461 shares traded. Becton, Dickinson and Company (NYSE:BDX) has risen 19.79% since June 14, 2017 and is uptrending. It has outperformed by 7.22% the S&P500. Some Historical BDX News: ; 03/05/2018 – Becton Dickinson 2Q Loss/Shr 19c; 19/03/2018 – BECTON DICKINSON AND CO – DIVESTITURE WILL NOT HAVE A MATERIAL IMPACT TO BD REVENUE OR ADJUSTED EARNINGS FOR FISCAL 2018; 28/04/2018 – FDA: Becton Dickinson & Co.- BD MAX DNA MMK Lab Use, catalog no. 442828; 27/04/2018 – Becton Dickinson Names Alberto Mas President of Medical Segment; 15/05/2018 – SANDELL EXITED BDX IN 1Q: 13F; 03/05/2018 – Becton Dickinson Raises FY18 View To Adj EPS $10.90-Adj EPS $11.05; 21/04/2018 – DJ Becton Dickinson and Company, Inst Holders, 1Q 2018 (BDX); 03/05/2018 – Becton Dickinson 2Q Rev $4.22B; 22/03/2018 – U.S. FDA-CONCLUDED THAT STUDIES PERFORMED BY BD WERE ROBUST & SHOWED THERE WAS SIGNIFICANT CHANCE OF FALSE RESULTS WITH MAGELLAN’S LEADCARE TESTS; 26/04/2018 – FDA: Becton Dickinson & Company- BD Vacutainer® Push Button Blood Collection Set 0.6 x 19 mm x 305 mm 23G x ® x 12 (Catalog n

Among 20 analysts covering Becton Dickinson (NYSE:BDX), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. Becton Dickinson had 53 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, June 30, the company rating was upgraded by Raymond James. The stock of Becton, Dickinson and Company (NYSE:BDX) has “Buy” rating given on Thursday, November 2 by Stifel Nicolaus. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, February 7. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, January 4. Citigroup maintained Becton, Dickinson and Company (NYSE:BDX) rating on Thursday, February 4. Citigroup has “Neutral” rating and $146 target. The stock of Becton, Dickinson and Company (NYSE:BDX) has “Outperform” rating given on Tuesday, October 24 by Wells Fargo. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, November 3. As per Friday, September 22, the company rating was initiated by Wells Fargo. As per Wednesday, December 20, the company rating was maintained by Cowen & Co. The firm earned “Hold” rating on Friday, November 3 by RBC Capital Markets.

Analysts await Becton, Dickinson and Company (NYSE:BDX) to report earnings on August, 2. They expect $2.84 EPS, up 15.45% or $0.38 from last year’s $2.46 per share. BDX’s profit will be $758.85 million for 20.44 P/E if the $2.84 EPS becomes a reality. After $2.65 actual EPS reported by Becton, Dickinson and Company for the previous quarter, Wall Street now forecasts 7.17% EPS growth.

More news for Becton, Dickinson and Company (NYSE:BDX) were recently published by: Nasdaq.com, which released: “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …” on June 11, 2018. Streetinsider.com‘s article titled: “Becton Dickinson (BDX) Names John DeFord as CTO” and published on June 01, 2018 is yet another important article.

Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.50, from 1.55 in 2017Q4. It dived, as 69 investors sold BDX shares while 375 reduced holdings. 114 funds opened positions while 350 raised stakes. 219.77 million shares or 1.86% more from 215.77 million shares in 2017Q4 were reported. Vanguard Inc holds 0.2% of its portfolio in Becton, Dickinson and Company (NYSE:BDX) for 21.10 million shares. Wheatland Advisors holds 1.19% or 6,650 shares in its portfolio. Reliance Trust Communication Of Delaware has 3,468 shares. Howland Cap Llc holds 0.09% or 5,138 shares. Scotia Capital has 0.16% invested in Becton, Dickinson and Company (NYSE:BDX). Findlay Park Ltd Liability Partnership stated it has 1.60 million shares. Nomura Asset Mngmt Commerce Ltd accumulated 0.18% or 76,923 shares. Moreover, South State Corporation has 0.31% invested in Becton, Dickinson and Company (NYSE:BDX). Peapack Gladstone Fincl Corp invested 0% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Pathstone Family Office Ltd accumulated 1.71% or 14,089 shares. 53,363 are held by Shell Asset Mngmt Com. Carnegie Asset Ltd owns 1,894 shares or 0.04% of their US portfolio. Clarivest Asset Ltd Liability, California-based fund reported 733 shares. Edgestream Prns Lp accumulated 3,949 shares or 0.17% of the stock. 2,186 are held by Motley Fool Asset Mngmt Ltd Co.

Since February 23, 2018, it had 1 insider purchase, and 6 insider sales for $9.39 million activity. The insider Gallagher John E sold $1.21M. Melcher David F bought $112,535 worth of stock. $910,726 worth of stock was sold by Borzi James W on Monday, February 26. $38,416 worth of Becton, Dickinson and Company (NYSE:BDX) shares were sold by RING TIMOTHY M. $426,079 worth of stock was sold by Polen Thomas E Jr on Tuesday, March 13. Conroy Alexandre had sold 20,128 shares worth $4.60M on Monday, May 21. Shabshab Nabil had sold 10,209 shares worth $2.31 million.

Analysts await Abeona Therapeutics Inc. (NASDAQ:ABEO) to report earnings on August, 21. They expect $-0.19 EPS, up 9.52% or $0.02 from last year’s $-0.21 per share. After $-0.18 actual EPS reported by Abeona Therapeutics Inc. for the previous quarter, Wall Street now forecasts 5.56% negative EPS growth.

More recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Crainscleveland.com which released: “Abeona Therapeutics opens The Elisa Linton Center for Rare Disease Therapies” on June 11, 2018. Also Seekingalpha.com published the news titled: “Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?” on May 29, 2018. Streetinsider.com‘s news article titled: “Abeona Therapeutics (ABEO) Updates Clinical Data from Phase 1/2 Trial for EB-101 Gene Therapy in Epidermolysis …” with publication date: May 17, 2018 was also an interesting one.

Among 11 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $36.0 highest and $6.0 lowest target. $26.78’s average target is 70.57% above currents $15.7 stock price. Abeona Therapeutics had 48 analyst reports since December 16, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, June 1. H.C. Wainwright maintained the shares of ABEO in report on Thursday, January 4 with “Buy” rating. The company was maintained on Friday, October 6 by Cantor Fitzgerald. The stock has “Buy” rating by Jefferies on Friday, January 6. The company was maintained on Thursday, May 25 by FBR Capital. As per Tuesday, June 5, the company rating was maintained by H.C. Wainwright. Seaport Global initiated it with “Buy” rating and $2900 target in Tuesday, June 5 report. Cantor Fitzgerald maintained the shares of ABEO in report on Tuesday, March 20 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Monday, May 21. The firm has “Buy” rating given on Friday, April 20 by H.C. Wainwright.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $742.69 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Becton, Dickinson and Company (NYSE:BDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: